Abdallah S R Mohamed1, Carlos E Cardenas2, Adam S Garden3, Musaddiq J Awan4, Crosby D Rock3, Sarah A Westergaard3, G Brandon Gunn3, Abdelaziz M Belal5, Ahmed G El-Gowily5, Stephen Y Lai6, David I Rosenthal3, Clifton D Fuller7, Michalis Aristophanous8. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, University of Alexandria, Egypt. 2. Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, USA. 3. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. 4. Department of Radiation Oncology, Case Western Reserve University, Cleveland, USA. 5. Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, University of Alexandria, Egypt. 6. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA. 7. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: cdfuller@mdanderson.org. 8. Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: MAristophanous@mdanderson.org.
Abstract
BACKGROUND: To identify the radio-resistant subvolumes in pretreatment FDG-PET by mapping the spatial location of the origin of tumor recurrence after IMRT for head-and-neck squamous cell cancer to the pretreatment FDG-PET/CT. METHODS: Patients with local/regional recurrence after IMRT with available FDG-PET/CT and post-failure CT were included. For each patient, both pre-therapy PET/CT and recurrence CT were co-registered with the planning CT (pCT). A 4-mm radius was added to the centroid of mapped recurrence growth target volumes (rGTV's) to create recurrence nidus-volumes (NVs). The overlap between boost-tumor-volumes (BTV) representing different SUV thresholds/margins combinations and NVs was measured. RESULTS: Forty-seven patients were eligible. Forty-two (89.4%) had type A central high dose failure. Twenty-six (48%) of type A rGTVs were at the primary site and 28 (52%) were at the nodal site. The mean dose of type A rGTVs was 71Gy. BTV consisting of 50% of the maximum SUV plus 10mm margin was the best subvolume for dose boosting due to high coverage of primary site NVs (92.3%), low average relative volume to CTV1 (41%), and least average percent voxels outside CTV1 (19%). CONCLUSIONS: The majority of loco-regional recurrences originate in the regions of central-high-dose. When correlated with pretreatment FDG-PET, the majority of recurrences originated in an area that would be covered by additional 10mm margin on the volume of 50% of the maximum FDG uptake.
BACKGROUND: To identify the radio-resistant subvolumes in pretreatment FDG-PET by mapping the spatial location of the origin of tumor recurrence after IMRT for head-and-neck squamous cell cancer to the pretreatment FDG-PET/CT. METHODS:Patients with local/regional recurrence after IMRT with available FDG-PET/CT and post-failure CT were included. For each patient, both pre-therapy PET/CT and recurrence CT were co-registered with the planning CT (pCT). A 4-mm radius was added to the centroid of mapped recurrence growth target volumes (rGTV's) to create recurrence nidus-volumes (NVs). The overlap between boost-tumor-volumes (BTV) representing different SUV thresholds/margins combinations and NVs was measured. RESULTS: Forty-seven patients were eligible. Forty-two (89.4%) had type A central high dose failure. Twenty-six (48%) of type A rGTVs were at the primary site and 28 (52%) were at the nodal site. The mean dose of type A rGTVs was 71Gy. BTV consisting of 50% of the maximum SUV plus 10mm margin was the best subvolume for dose boosting due to high coverage of primary site NVs (92.3%), low average relative volume to CTV1 (41%), and least average percent voxels outside CTV1 (19%). CONCLUSIONS: The majority of loco-regional recurrences originate in the regions of central-high-dose. When correlated with pretreatment FDG-PET, the majority of recurrences originated in an area that would be covered by additional 10mm margin on the volume of 50% of the maximum FDG uptake.
Authors: Fréderic Duprez; Wilfried De Neve; Werner De Gersem; Marc Coghe; Indira Madani Journal: Int J Radiat Oncol Biol Phys Date: 2010-07-17 Impact factor: 7.038
Authors: Indira Madani; Wim Duthoy; Cristina Derie; Werner De Gersem; Tom Boterberg; Micky Saerens; Filip Jacobs; Vincent Grégoire; Max Lonneux; Luc Vakaet; Barbara Vanderstraeten; Wouter Bauters; Katrien Bonte; Hubert Thierens; Wilfried De Neve Journal: Int J Radiat Oncol Biol Phys Date: 2007-05-01 Impact factor: 7.038
Authors: Piet Dirix; Vincent Vandecaveye; Frederik De Keyzer; Sigrid Stroobants; Robert Hermans; Sandra Nuyts Journal: J Nucl Med Date: 2009-06-12 Impact factor: 10.057
Authors: Omar A Zeidan; Katja M Langen; Sanford L Meeks; Rafael R Manon; Thomas H Wagner; Twyla R Willoughby; D Wayne Jenkins; Patrick A Kupelian Journal: Int J Radiat Oncol Biol Phys Date: 2006-12-29 Impact factor: 7.038
Authors: L A Dawson; Y Anzai; L Marsh; M K Martel; A Paulino; J A Ship; A Eisbruch Journal: Int J Radiat Oncol Biol Phys Date: 2000-03-15 Impact factor: 7.038
Authors: Hugo J W L Aerts; Angela A W van Baardwijk; Steven F Petit; Claudia Offermann; Judith van Loon; Ruud Houben; Anne-Marie C Dingemans; Rinus Wanders; Liesbeth Boersma; Jacques Borger; Gerben Bootsma; Wiel Geraedts; Cordula Pitz; Jean Simons; Bradly G Wouters; Michel Oellers; Philippe Lambin; Geert Bosmans; Andre L A J Dekker; Dirk De Ruysscher Journal: Radiother Oncol Date: 2009-03-28 Impact factor: 6.280
Authors: Pierluigi Bonomo; A Merlotti; E Olmetto; A Bianchi; I Desideri; A Bacigalupo; P Franco; C Franzese; E Orlandi; L Livi; S Caini Journal: Eur J Nucl Med Mol Imaging Date: 2018-06-09 Impact factor: 9.236
Authors: J Beaumont; O Acosta; A Devillers; X Palard-Novello; E Chajon; R de Crevoisier; J Castelli Journal: EJNMMI Res Date: 2019-09-18 Impact factor: 3.138
Authors: Lisanne V van Dijk; Steven J Frank; Ying Yuan; Brandon Gunn; Amy C Moreno; Abdallah S R Mohamed; Kathryn E Preston; Yun Qing; Michael T Spiotto; William H Morrison; Anna Lee; Jack Phan; Adam S Garden; David I Rosenthal; Johannes A Langendijk; Clifton D Fuller Journal: Clin Transl Radiat Oncol Date: 2021-11-11
Authors: Hesham Elhalawani; Carlos E Cardenas; Stefania Volpe; Souptik Barua; Sonja Stieb; Calvin B Rock; Timothy Lin; Pei Yang; Haijun Wu; Jhankruti Zaveri; Baher Elgohari; Lamiaa E Abdallah; Amit Jethanandani; Abdallah S R Mohamed; Laurence E Court; Katherine A Hutcheson; G Brandon Gunn; David I Rosenthal; Steven J Frank; Adam S Garden; Arvind Rao; Clifton D Fuller Journal: Clin Transl Radiat Oncol Date: 2021-06-06